GLP1R and pancreatic neoplasm: Moreover, there are reports that use of the current marketable forms of longer half-life peptide GLP-1 receptor agonists are associated with complications such as the risk of hypoglycemia, abdominal pain, pancreatitis, pancreatic cancer and thyroid cancer18,19.